Alternative Isotope Options for Amyloidosis Imaging: A Technologist's Perspective

Area of Science:

• Nuclear medicine
• Cardiology
• Radiochemistry

Background:

• Shortages of technetium-99m-pyrophosphate (PYP) limit cardiac amyloidosis diagnosis.
• Technetium-99m-hydroxymethylene diphosphonate (HMDP) is a widely available alternative radiotracer.

Purpose of the Study:

• To evaluate the utility of 99mTc-HMDP as an alternative to 99mTc-PYP for diagnosing cardiac amyloidosis.
• To compare the efficacy, imaging protocols, and interpretation of 99mTc-HMDP and 99mTc-PYP.

Main Methods:

• Comparison of blood clearance and sensitivity between 99mTc-HMDP and 99mTc-PYP.
• Review of imaging protocols and interpretation guidelines for 99mTc-HMDP.
• Analysis of potential challenges, such as soft-tissue uptake, with 99mTc-HMDP.

Main Results:

• 99mTc-HMDP demonstrates comparable blood clearance and sensitivity to 99mTc-PYP.
• Imaging protocols are similar, with 99mTc-HMDP imaged 2-3 hours post-injection.
• Interpretation is similar, though high soft-tissue uptake with 99mTc-HMDP requires caution.

Conclusions:

• 99mTc-HMDP is a viable alternative radiotracer for diagnosing cardiac amyloidosis, especially during PYP shortages.
• The diagnostic performance and imaging approach for 99mTc-HMDP are comparable to 99mTc-PYP.
• Awareness of 99mTc-HMDP's soft-tissue uptake characteristics is crucial for accurate interpretation.